Sippican Capital Advisors Buys 2,129 Shares of Merck & Co., Inc. (NYSE:MRK)

Sippican Capital Advisors grew its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 11.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,442 shares of the company’s stock after acquiring an additional 2,129 shares during the quarter. Merck & Co., Inc. comprises approximately 1.5% of Sippican Capital Advisors’ portfolio, making the stock its 29th biggest position. Sippican Capital Advisors’ holdings in Merck & Co., Inc. were worth $1,576,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of MRK. Norges Bank bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at $2,250,767,000. Nuveen Asset Management LLC increased its holdings in shares of Merck & Co., Inc. by 20.4% during the fourth quarter. Nuveen Asset Management LLC now owns 24,251,965 shares of the company’s stock valued at $1,983,811,000 after acquiring an additional 4,112,158 shares in the last quarter. California Public Employees Retirement System increased its holdings in shares of Merck & Co., Inc. by 31.6% during the fourth quarter. California Public Employees Retirement System now owns 13,542,412 shares of the company’s stock valued at $1,107,769,000 after acquiring an additional 3,252,367 shares in the last quarter. Morgan Stanley increased its holdings in shares of Merck & Co., Inc. by 16.7% during the fourth quarter. Morgan Stanley now owns 22,569,366 shares of the company’s stock valued at $1,846,174,000 after acquiring an additional 3,221,509 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. increased its holdings in shares of Merck & Co., Inc. by 25.8% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 11,822,416 shares of the company’s stock valued at $967,060,000 after acquiring an additional 2,428,079 shares in the last quarter. Hedge funds and other institutional investors own 72.86% of the company’s stock.

Shares of NYSE:MRK opened at $77.47 on Friday. The stock has a market capitalization of $196.03 billion, a price-to-earnings ratio of 17.14, a PEG ratio of 1.89 and a beta of 0.43. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.00 and a current ratio of 1.30. The stock’s 50-day simple moving average is $75.64 and its two-hundred day simple moving average is $78.72. Merck & Co., Inc. has a 52-week low of $71.71 and a 52-week high of $87.80.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Wednesday, February 3rd. The company reported $1.32 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.38 by ($0.06). Merck & Co., Inc. had a net margin of 24.33% and a return on equity of 53.83%. The company had revenue of $12.51 billion for the quarter, compared to analysts’ expectations of $12.65 billion. During the same period in the previous year, the firm earned $1.16 earnings per share. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. As a group, equities analysts forecast that Merck & Co., Inc. will post 5.9 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 7th. Stockholders of record on Monday, March 15th were given a dividend of $0.65 per share. The ex-dividend date of this dividend was Friday, March 12th. This represents a $2.60 dividend on an annualized basis and a dividend yield of 3.36%. Merck & Co., Inc.’s payout ratio is currently 50.10%.

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Merck & Co., Inc. in a report on Friday, February 5th. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Merck & Co., Inc. has a consensus rating of “Buy” and a consensus target price of $96.27.

About Merck & Co., Inc.

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as and vaccine products.

Featured Story: Risk Tolerance

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.